The SEQENS Group, a global partner in health, personal care and specialty ingredients, is excited to announce a strategic partnership with APPLEXION, a historic & global supplier of purification technologies. SEQENS*, through Protéus, has developed a long-standing expertise in enzyme discovery, optimization, and biocatalytic process implementation, while APPLEXION is a world-class leader in developing, designing, supplying, and installing purification technology-based processes and industrial units across various markets.

This collaboration expands APPLEXION’s catalog of consumables by appointing them as the exclusive distributor of SEQENZYM FT, an innovative enzymatic solution developed by SEQENS, in the specific market segment of agro-food industry. SEQENZYM FT has received the self-GRAS status in the USA based on evaluation by independent expert’s panelists and is believed to be among the leading enzymes on the market that demonstrate only fructosyl-transferase activity, efficiently converting sucrose into short-chain fructo-oligosaccharides (scFOS). SEQENZYM FT shows higher yield, lower free fructose and no color formation, compared to existing enzymes that may exhibit deleterious invertase activity.

Looking ahead, SEQENS and APPLEXION have committed to jointly develop new enzymes to serve as processing aids in the food industry, leveraging their combined expertise to drive innovation and enhance product offerings.

“By combining our strengths with APPLEXION, we are well-positioned to significantly impact the food processing aids enzyme industry by delivering unmatched solutions that meet the evolving needs of our customers” says Julien Boutet, Innovation & Biotechnologies Director at SEQENS.

“SEQENS and APPLEXION technologies are a perfect match to ensure robust production of prebiotics with higher yield and purity. APPLEXION digital services support these synergies for a day-to-day efficient production.” says Damien Brichant, President of APPLEXION.